Aravive Inc (NASDAQ:ARAV) has received an average recommendation of “Buy” from the seven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $26.00.
Several brokerages have commented on ARAV. ValuEngine downgraded shares of Aravive from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 14th. Zacks Investment Research downgraded shares of Aravive from a “buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Aravive in a research note on Thursday, April 30th.
NASDAQ ARAV traded up $0.70 during trading hours on Friday, hitting $14.81. The company’s stock had a trading volume of 229,700 shares, compared to its average volume of 173,276. The stock has a fifty day moving average of $12.91 and a 200 day moving average of $10.65. Aravive has a twelve month low of $3.34 and a twelve month high of $15.62. The firm has a market capitalization of $227.29 million, a P/E ratio of -7.88 and a beta of 3.51. The company has a quick ratio of 12.36, a current ratio of 12.36 and a debt-to-equity ratio of 0.12.
Several hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN increased its position in shares of Aravive by 22.3% during the first quarter. Wells Fargo & Company MN now owns 19,843 shares of the company’s stock worth $114,000 after acquiring an additional 3,616 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Aravive during the first quarter worth $32,000. Jane Street Group LLC bought a new stake in shares of Aravive during the first quarter worth $83,000. Wedbush Securities Inc. bought a new stake in shares of Aravive during the first quarter worth $92,000. Finally, UBS Group AG increased its position in shares of Aravive by 24.2% during the fourth quarter. UBS Group AG now owns 81,956 shares of the company’s stock worth $1,120,000 after acquiring an additional 15,952 shares in the last quarter. 41.74% of the stock is owned by institutional investors.
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Recommended Story: Circuit Breakers
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.